Search the Newsreel

Claritev signals $1.0B-$1.02B 2026 revenue outlook as bookings target stays at $100M

Earnings Call Insights: Claritev Corporation (CTEV) Q2 2026 MANAGEMENT VIEW * "We're pleased to announce another strong quarter for Claritev and continued progress on our turnaround journey." (CEO, President & Chairman Travis Dalton) "At our Investor Day in March, we introduced 2026 as the …

Noticias de acciones de Kimberly-Clark Corp (KMB)

Wie die durchwachsenen Ergebnisse des zweiten Quartals und die Innovation rund um Hesperaloe-Fasern bei Kimberly-Clark (KMB) das Anlagepotenzial des Unternehmens verändert haben

Cómo los resultados dispares del segundo trimestre y la innovación en fibra de Hesperaloe de Kimberly-Clark (KMB) han cambiado su perspectiva de inversión

How Mixed Q2 Results And Hesperaloe Fiber Innovation At Kimberly-Clark (KMB) Have Changed Its Investment Story

Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 6% - Here's What Happened

Can Clarivate’s (CLVT) Agentic AI Push Deepen Its Moat Or Signal A Riskier Shift?

Clarivate Plc recently expanded agentic AI capabilities across its Cortellis portfolio, embedding natural language and multi‑agent tools into life sciences R&D, safety and competitive intelligence workflows to cut manual effort and speed evidence-based decisions. This move effectively turns Cortellis into a more embedded decision …

Claritev Stock (CTEV) Opinions on Q2 Earnings Beat

Claritev earnings beat by $0.67, revenue topped estimates

CTEV | Claritev Corporation Financials - Income Statement

Kimberly-Clark to Consolidate Operations, Invest in Digital Optimizations Ahead of Kenvue Acquisition

Kimberly-Clark is preparing for its acquisition of Kenvue by consolidating 6,000 applications and over 15 ERP systems, aiming for significant cost savings and operational efficiencies. The company plans to integrate supply chain and commercial operations, standardize IT infrastructure, and deploy AI across various functions. …

Earnings call transcript: Claritev posts Q2 2026 beat, but shares fall premarket

Claritev (NYSE:CTEV) Trading 41.9% Higher After Strong Earnings

Clarus Corp Q2 2026: Revenue $56.2M, EPS $0.12— 10-Q Summary

Clarus Corp (CLAR) reported its Q2 2026 financial results, showing a revenue of $56.2 million and diluted earnings per share of $0.12, improving from a net loss in the previous year. The company's year-to-date sales increased by 2.1% to $118.1 million, largely due to …

Clarus Posts $4.7M Profit After $6.1M Tariff Refund

Clarus (NASDAQ: CLAR) reported a net income of $4.7 million in Q2 2026, a significant improvement from an $8.4 million loss in the prior year, largely due to a $6.1 million IEEPA tariff refund. Sales increased slightly to $56.2 million, with the Outdoor segment …

Clarus’ Q2 Profits Boosted by Tariff Refunds, Black Diamond’s Sales Trends Improve

Clarus Corp. reported a significant recovery in Q2 2026 earnings, driven by tariff refunds and strong underlying performance, especially from its Outdoor segment led by Black Diamond. The company exceeded sales and adjusted EBITDA guidance, saw improved gross margins across both segments, and completed …

Pacer Advisors Inc. Reduces Stock Position in Kimberly-Clark Corporation $KMB

Pacer Advisors Inc. significantly reduced its stake in Kimberly-Clark Corporation (NASDAQ:KMB) by 23.7% in the first quarter, selling 9,879 shares and retaining 31,832 shares valued at $3.07 million. This comes as Kimberly-Clark reported Q1 earnings and revenue that missed analyst estimates, although revenue still …

Claritev Corporation (CTEV) Reports Q2 Loss, Tops Revenue Estimates

Claritev Updates 2026 Revenue Guidance to $1B-$1.02B After Q2

Sarasin & Partners LLP Reduces Stock Position in Kimberly-Clark Corporation $KMB

Sarasin & Partners LLP significantly reduced its stake in Kimberly-Clark Corporation ($KMB) by 48.9% in the second quarter, selling over 668,000 shares but still retaining a substantial holding. Despite this, institutional investors collectively own a majority of Kimberly-Clark's stock. The company recently reported quarterly …

Yuma Welcomes $100 Million Kimberly-Clark Manufacturing Facility

Kimberly-Clark Corporation is constructing a new 50,000-square-foot pilot facility in Yuma, Arizona, representing a capital investment of over $100 million. This facility will create approximately 50 full-time jobs and focus on extracting useful fibers from hesperaloe for future hygiene products. The project highlights Yuma's …

Aclaris Therapeutics (NASDAQ: ACRS) widens loss as R&D spending accelerates

Aclaris Therapeutics reported a widened net loss of $41.329 million for the first half of 2026, primarily due to increased research and development (R&D) spending on its immuno-inflammatory programs like bosakitug, ATI-052, modzatinib, and ATI-9494. Despite the losses, the company maintains $170.6 million in …

Knowledge graphs: Turning fragmented biomedical data into connected, actionable insight

This article discusses how knowledge graphs address the challenge of fragmented biomedical data, transforming it into actionable insights. It highlights that the problem is not data abundance but usability, with knowledge graphs connecting disparate data points into a unified framework. The piece also explains …

Owens Corning (OC) Is Up 8.5% After Q2 Earnings Beat, Buybacks And CFO Transition – What's Changed

In early August 2026, Owens Corning reported second-quarter 2026 results showing broadly flat sales at US$2,756 million year on year, but a decline in net income to US$226 million and lower earnings per share compared with the prior-year quarter. Alongside these results, the company …

Clarus Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CLAR) 2026-08-07

CLAR Q2 Deep Dive: Margin Recovery, Operational Simplification, and Strategic Review Shape Outlook

Clarivate Plc (CLVT) Stock Forecasts

Clarivate Plc (CLVT) is a data, information, and software workflow solutions company, primarily serving academia, government, law, life sciences, and healthcare sectors. An analyst report from Morningstar on August 6, 2026, suggests that Clarivate is in the early stages of a multiyear turnaround. The …

Clarus (NASDAQ:CLAR) Releases Quarterly Earnings Results

Clarus Q2 Results: Adjusted EPS beats estimate, sales rise 1.65% YoY

Clarus (NASDAQ: CLAR) reported strong Q2 results with an adjusted EPS of $0.18, significantly beating the analyst estimate of $(0.09) by 300% and marking a substantial turnaround from a loss last year. The company's sales increased by 1.65% year-over-year to $56.156 million, also surpassing …

Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates

Aclaris Therapeutics Inc (NASDAQ: ACRS) reported a second-quarter EPS of $-0.150, surpassing analyst estimates by $0.01. The company also exceeded revenue expectations, bringing in $1.6M against a consensus of $1.38M. Aclaris Therapeutics' stock has shown strong performance, increasing by 29.010% in the last three …

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib for Moderate to Severe Lichen Planus

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has been granted Fast Track Designation by the FDA for its investigational drug modzatinib, intended for the treatment of moderate to severe lichen planus. This designation will expedite the development and review process for the therapy, which currently has …

Clarus earnings beat by $0.25, revenue topped estimates

Aclaris Therapeutics (ACRS) Releases Q2 2026 Earnings: Revenue Declines, Losses Narrow

Lake Street Capital Forecasts Clarus Q2 Earnings

FDA grants fast track status to Aclaris’ lichen planus drug By Investing.com

Aclaris Therapeutics Inc. (NASDAQ:ACRS) has received Fast Track Designation from the FDA for its drug modzatinib (ATI-2138) to treat moderate to severe lichen planus. This designation will accelerate the development and review process for the drug, which addresses an unmet medical need as there …